Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 5/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | GBA1 | P04062 | 2/20 | 0.37 |
| ▸ | PPARA | Q07869 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.34 |
| ▸ | ADH1C | P00326 | 1/20 | 0.34 |
| ▸ | ADH1A | P07327 | 1/20 | 0.34 |
| ▸ | ADH4 | P08319 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4469236 | 0.97 | DNM1 (0.48) | DNM1TSHRALDH1A1EPHX1THRB | |
| SCHEMBL4465244 | 0.97 | DNM1 (0.48) | DNM1TSHRALDH1A1EPHX1THRB | |
| SCHEMBL181643 | 0.92 | TSHR (0.36) | DNM1TSHRALDH1A1EPHX1THRB | |
| SCHEMBL1793429 | 0.89 | TSHR (0.48) | DNM1TSHRALDH1A1EPHX1THRB | |
| SCHEMBL1793433 | 0.89 | TSHR (0.48) | DNM1TSHRALDH1A1EPHX1THRB | |
| SCHEMBL1794716 | 0.86 | EPHX1 (0.48) | DNM1TSHRALDH1A1EPHX1THRB | |
| SCHEMBL1794187 | 0.86 | EPHX1 (0.48) | DNM1TSHRALDH1A1EPHX1THRB | |
| SCHEMBL1795018 | 0.86 | EPHX1 (0.48) | DNM1TSHRALDH1A1EPHX1THRB | |
| SCHEMBL1795020 | 0.86 | EPHX1 (0.48) | DNM1TSHRALDH1A1EPHX1THRB | |
| SCHEMBL15477622 | 0.86 | EPHX1 (0.48) | DNM1TSHRALDH1A1EPHX1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2098316-A2 | Metal nanoparticles stabilized with a bident amine | Xerox Corporation (US) | 2009-09-09 | — | — | EP | claimed |
| US-20090214764-A1 | METAL NANOPARTICLES STABILIZED WITH A BIDENT AMINE | XEROX CORPORATION (US) | 2009-08-27 | — | — | US | claimed |
| US-10829442-B2 | Process for the preparation of carbamates | TAMINCO BVBA (BE) | 2020-11-10 | — | — | US | disclosed |
| US-20190169115-A1 | IMPROVED PROCESS FOR THE PREPARATION OF CARBAMATES | TAMINCO BVBA (BE) | 2019-06-06 | — | — | US | disclosed |
| EP-3279185-B1 | IMPROVED PROCESS FOR THE PREPARATION OF CARBAMATES | TAMINCO BVBA (BE) | 2018-11-14 | — | — | EP | disclosed |
| WO-2018024828-A1 | IMPROVED PROCESS FOR THE PREPARATION OF CARBAMATES | TAMINCO BVBA (BE) | 2018-02-08 | — | — | WO | disclosed |
| EP-3279185-A1 | IMPROVED PROCESS FOR THE PREPARATION OF CARBAMATES | Taminco bvba (BE) | 2018-02-07 | — | — | EP | disclosed |
| US-20110245772-A1 | FOCAL CALCIUM CHANNEL MODULATION | THE JOHN HOPKINS UNIVERSITY (US) | 2011-10-06 | — | — | US | disclosed |
| US-8003618-B2 | modulating activity of calcium channel in pre-determined region of tissue or organ of mammal by contacting region with nucleic acid encoding GEM protein or variant thereof under conditions sufficient to express GEM protein within region at level sufficient to modulate activity of calcium channel | THE JOHN HOPKINS UNIVERSITY (US) | 2011-08-23 | — | — | US | disclosed |
| EP-2098316-A2 | Metal nanoparticles stabilized with a bident amine | Xerox Corporation (US) | 2009-09-09 | — | — | EP | disclosed |
| US-20090214764-A1 | METAL NANOPARTICLES STABILIZED WITH A BIDENT AMINE | XEROX CORPORATION (US) | 2009-08-27 | — | — | US | disclosed |
| US-20040204376-A1 | Focal calcium channel modulation | THE JOHNS HOPKINS UNIVERSITY | 2004-10-14 | — | — | US | disclosed |
| WO-2004030630-A2 | FOCAL CALCIUM CHANNEL MODULATION | THE JOHNS HOPKINS UNIVERSITY (US) | 2004-04-15 | — | — | WO | disclosed |
| US-20020127275-A1 | Slow release pharmaceutical compositions and methods of preparation | BASF CORPORATION | 2002-09-12 | — | — | US | disclosed |
| US-20020110595-A1 | Slow release pharmaceutical compositions | BASF CORPORATION | 2002-08-15 | — | — | US | disclosed |
| EP-0965341-A2 | Combination of dofetilide and a calcium channel blocker | Pfizer Products Inc. (US) | 1999-12-22 | — | — | EP | disclosed |
| WO-1998000143-A1 | SLOW RELEASE PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING SAME | KNOLL PHARMACEUTICAL COMPANY (US) | 1998-01-08 | — | — | WO | disclosed |
| EP-0422728-B1 | Process for the preparation of dispersant viscosity index improvers | SHELL INT RESEARCH (NL) | 1995-01-11 | — | — | EP | disclosed |
| US-5073600-A | Aminated graft polymer oil additive | SHELL OIL COMPANY (US) | 1991-12-17 | — | — | US | disclosed |
| EP-0422728-A1 | Process for the preparation of dispersant viscosity index improvers | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1991-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10829442-B2 | Process for the preparation of carbamates | CPS1, GLUL, CBR3 | DNM1 3563/4885TSHR 1833/4885ALDH1A1 932/4885 |
| US-20190169115-A1 | IMPROVED PROCESS FOR THE PREPARATION OF CARBAMATES | CPS1, GLUL, C9 | DNM1 3844/4885TSHR 1994/4885ALDH1A1 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.